April 2018 article by CNBC.

While “gene therapy” treatments can offer tremendous benefits to patients and society, they limit the potential earnings for those investing in the technology. Curing patients means no recurring revenue, and in the case of infectious disease, shrinks the pool of new patients.

“Richter cited Gilead Sciences’ treatments for hepatitis C, which achieved cure rates of more than 90 percent. The company’s U.S. sales for these hepatitis C treatments peaked at $12.5 billion in 2015, but have been falling ever since. Goldman estimates the U.S. sales for these treatments will be less than $4 billion this year, according to a table in the report.”

Read More